Novavax, Inc. (NASDAQ: NVAX) has provided updates regarding its late-stage coronavirus study. The company has disclosed that it is planning to commence Phase III Clinical trial in Mexico and the US in the coming week. NVAX has also arranged alternative clinical sites to use
